

# Gastrointestinal Symptoms are Still Prevalent and Negatively Impact Health-Related Quality of Life: A Large Cross-Sectional Population Based Study in The Netherlands

Merel M. Tielemans<sup>1,2\*</sup>, Jeroen Jaspers Focks<sup>3</sup>, Leo G. M. van Rossum<sup>4</sup>, Ties Eikendal<sup>1</sup>, Jan B. M. J. Jansen<sup>1,5</sup>, Robert J. F. Laheij<sup>2</sup>, Martijn G. H. van Oijen<sup>2,6</sup>

**1** Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, the Netherlands, **2** Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, the Netherlands, **3** Department of Cardiology, Radboud University Medical Center, Nijmegen, the Netherlands, **4** Department of Epidemiology, Biostatistics and Health Technology Assessment, Radboud University Medical Center, Nijmegen, the Netherlands, **5** Department of Gastroenterology and Hepatology, Elkerliek Hospital, Helmond, the Netherlands, **6** Division of Digestive Diseases, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America

## Abstract

**Background:** Over the last decades important risk factors for gastrointestinal symptoms have shifted, which may have changed its population prevalence. The aim of this study was to assess the current prevalence of gastrointestinal symptoms, appraise associated factors and assess health-related quality of life in the general population.

**Methods:** A total of 51,869 questionnaires were sent to a representative sample of the Dutch adult general population in December 2008. Demographic characteristics, gastrointestinal symptoms, health-related quality of life, medication use and co-morbidity were reported. We used multivariable logistic regression analysis to determine factors associated with gastrointestinal symptoms.

**Results:** A total of 18,317 questionnaires were returned, and 16,758 were eligible for analysis. Prevalence of gastrointestinal symptoms was 26%. Most frequent symptoms were bloating (63%), borborygmi (60%) and flatulence (71%). Female gender (adjusted OR (aOR) 1.59, 95% CI 1.43–1.77), asthma/COPD (aOR 1.47, 95% CI 1.21–1.79), use of paracetamol (aOR 1.33, 95% CI 1.20–1.47), antidepressants (aOR 1.56, 95% CI 1.22–2.00) and acid-suppressive medication were independently associated with presence of gastrointestinal symptoms. Age over 65 years (aOR 0.75, 95% CI 0.65–0.87), and use of statins (aOR 0.75, 95% CI 0.61–0.93) were associated with a lower prevalence of gastrointestinal symptoms. Respondents with gastrointestinal symptoms had a lower mean health-related quality of life of 0.81 (SD=0.21) compared to 0.92 (SD=0.14) for persons without gastrointestinal symptoms ( $P<0.01$ ).

**Conclusions:** Prevalence of gastrointestinal symptoms in the Dutch community is high and associated with decreased health-related quality of life.

**Citation:** Tielemans MM, Jaspers Focks J, van Rossum LGM, Eikendal T, Jansen JBMJ, et al. (2013) Gastrointestinal Symptoms are Still Prevalent and Negatively Impact Health-Related Quality of Life: A Large Cross-Sectional Population Based Study in The Netherlands. PLoS ONE 8(7): e69876. doi:10.1371/journal.pone.0069876

**Editor:** Hamid Reza Baradaran, Iran University of Medical Sciences, Islamic Republic of Iran

**Received:** March 21, 2013; **Accepted:** June 14, 2013; **Published:** July 29, 2013

**Copyright:** © 2013 Tielemans et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** This study was sponsored by an unrestricted research grant of Nycomed BV, the Netherlands. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have read the journal's policy and have the following conflicts: None of the authors are employees by Nycomed BV. Martijn G. H. van Oijen received unrestricted research grants from AstraZeneca, Nycomed BV, Janssen and Shire. He received consulting fees from Pfizer and AstraZeneca BV. Other authors do not have conflicts of interest. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

\* E-mail: M.Tielemans@MDL.umcn.nl

## Introduction

Gastrointestinal symptoms are highly prevalent in the general population and are a frequent cause for consultation of a general practitioner [1]. Individuals with gastrointestinal symptoms contribute heavily to healthcare utilization and budgeting. The yearly costs for individual patients with gastrointestinal symptoms are steep. For example, in the United States average direct healthcare costs for a number of symptoms such as constipation

(\$7522), functional abdominal pain (\$7646) and irritable bowel syndrome (\$5049) are considerable [2].

Large population studies in Western countries reported a widely ranging prevalence of dyspepsia from 10% to more than 50% [1,3–12]. However, these studies were performed about 20 years ago and the risk factor profile for gastrointestinal symptoms has shifted since. For example, the incidence of *Helicobacter pylori* has rapidly decreased in the industrialized world [13,14], while use of proton pump inhibitors (PPIs) has been on the rise [15–17].

Simultaneously, use of gastrototoxic medication, e.g. non-steroidal anti-inflammatory drugs (NSAIDs) and low-dose aspirin, is high [18]. Finally, there is a global epidemic of obesity, which is associated with gastrointestinal symptoms and disorders, especially gastroesophageal reflux disease (GERD) [19,20]. The overall prevalence of upper gastrointestinal symptoms ranged from 24% to 45% in a recent study in 13 European countries [21]. Although performed in the current era, this study emphasized on socioeconomic factors, and did not report associations between gastrointestinal symptoms and modifiable factors such as BMI and smoking on an individual level [21].

Health-related quality of life is an important parameter in modern medicine and refers to the extent that an individual's physical, emotional and social well-being is affected by a medical condition and its treatment. Individuals with gastrointestinal symptoms report a lower health-related quality of life [22–24], but this has been mainly studied in a subgroup of patients that have presented to a healthcare provider, which may not be a representative group. The exact impact of gastrointestinal symptoms on all domains of health related quality of life in the general –including non-healthcare visiting- population remains unclear.

Given abovementioned considerations, new data on the prevalence of gastrointestinal symptoms in the general population are warranted. We hypothesize that the prevalence, despite all changes, has remained stable. The aims of our study were to assess: 1) the prevalence of gastrointestinal symptoms in the general population; 2) factors associated with presence of gastrointestinal symptoms; and 3) the effect of gastrointestinal symptom presence on health-related quality of life.

## Materials and Methods

### Study Population

We sent 51,869 questionnaires by postal mail to a sample of the Dutch population in December 2008. Invited subjects were at least 18 years and randomly selected from municipal databases of five


different municipalities. These villages and cities were selected on their geographical location in The Netherlands, in order to fetch a representative sample. We included returned questionnaires until the end of March 2009. We excluded returned questionnaires with (1) missing of all baseline variables, (2) missing of all gastrointestinal symptoms, (3) missing of the primary outcome measure, or (4) unreadable input about medication use.

The Medical Ethical Committee of the Radboud University Nijmegen assessed the proposal of this study and concluded that it could be waived for ethical review, as questionnaires were returned and stored anonymously, and (non-)responders would not be contacted again. For this reason, we did not obtain written informed consent of all participants.

### Questionnaire

The questionnaire we used was specifically designed to assess demographic information, gastrointestinal symptoms, medication use, healthcare visits, and health-related quality of life, and has been used before [15,25,26]. Respondents were asked whether they suffer from gastrointestinal symptoms in general and subsequently for presence of 26 gastrointestinal symptoms including nausea, early satiety, bloating, constipation and diarrhoea. Severity of gastrointestinal symptoms was assessed on a seven-point Likert scale (0 = absent, 1 = almost absent, 2 = mild, 3 = moderate, 4 = moderately severe, 5 = severe, 6 = very severe) during the preceding four weeks [27]. A symptom was considered to be present when scored  $\geq 2$ .

Our primary outcome was the presence or absence of gastrointestinal symptoms, which was assessed with the question: “Do you experience gastrointestinal complaints?” and had to be answered with either “yes” or “no”. Secondary outcomes were type of gastrointestinal symptoms experienced in the preceding four weeks and health-related quality of life, which was assessed with the validated EQ-5D questionnaire [28]. The EQ-5D comprises 5 domains of health status: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each domain has 3 degrees of severity: no problems, some problems or extreme



**Figure 1. Flow chart.** \*Some respondents fulfilled more than 1 exclusion criterion. doi:10.1371/journal.pone.0069876.g001

**Table 1.** Population characteristics and factors associated with gastrointestinal symptom presence.

	Respondents with gastrointestinal symptoms	Respondents without gastrointestinal symptoms	Unadjusted OR (95% CI)	Adjusted OR (95% CI)
	n/N	n/N		
Mean age ( $\pm$ SD)	48.9 (16)	50.2 (16)	–	–
$\geq 65$ years (%)	747/4,300 (17)	2,451/12,389 (20)	0.85 (0.78–0.93)	0.75 (0.65–0.87)
Female (%)	2,784/4,217 (66)	6,448/12,079 (53)	1.70 (1.58–1.83)	1.59 (1.43–1.77)
Body mass index $\geq 25$ kg/m <sup>2</sup> (%)	2,067/4,224 (49)	5,549/12,213 (45)	1.15 (1.07–1.23)	1.02 (0.92–1.13)
Smoking (%)	840/4,247 (20)	2,089/12,242 (17)	1.20 (1.10–1.31)	1.12 (0.98–1.27)
Excessive alcohol consumption* (%)	394/2,919 (14)	1,229/9,266 (13)	1.02 (0.90–1.15)	0.93 (0.81–1.07)
Excessive coffee consumption† (%)	352/3,612 (10)	1,241/10,828 (12)	0.83 (0.74–0.95)	0.87 (0.74–1.02)
Co-morbidity (%)				
Diabetes mellitus	238/4,315 (6)	639/12,443 (5)	1.08 (0.93–1.26)	0.85 (0.64–1.13)
Rheumatoid arthritis	316/4,315 (7)	457/12,443 (4)	2.07 (1.79–2.40)	1.27 (0.99–1.62)
Asthma/COPD	393/4,315 (9)	651/12,443 (5)	1.82 (1.59–2.07)	1.47 (1.21–1.79)
Medication use				
PPIs <sup>‡</sup>	1,161/4,315 (27)	610/12,443 (5)	7.14 (6.43–7.94)	9.28 (7.91–10.9)
H2RAs**	212/4,315 (5)	75/12,443 (1)	8.52 (6.53–11.1)	9.93 (6.72–14.7)
Antacids	588/4,315 (14)	437/12,443 (4)	4.33 (3.81–4.93)	4.22 (3.53–5.05)
Paracetamol	2,529/4,315 (59)	5,763/12,443 (46)	1.64 (1.53–1.76)	1.33 (1.20–1.47)
NSAIDs <sup>§</sup>	1,076/4,315 (25)	2,157/12,443 (17)	1.58 (1.46–1.72)	1.02 (0.90–1.15)
Antiplatelet therapy <sup>¶</sup>	462/4,315 (11)	1,221/12,443 (10)	1.10 (0.98–1.23)	1.08 (0.89–1.30)
Antidepressants	278/4,315 (6)	423/12,443 (3)	1.96 (1.68–2.29)	1.56 (1.22–2.00)
Statins	435/4,315 (10)	1,285/12,443 (10)	0.97 (0.87–1.09)	0.75 (0.61–0.93)
Oral contraceptives	339/4,315 (8)	716/12,443 (6)	1.40 (1.22–1.60)	1.22 (0.99–1.51)
Beta blockers	487/4,315 (11)	1,286/12,443 (10)	1.10 (0.99–1.23)	0.87 (0.71–1.06)
ACE-inhibitors	227/4,315 (5)	727/12,443 (6)	0.90 (0.77–1.04)	0.81 (0.62–1.06)
Angiotensin-receptor antagonist	186/4,315 (4)	517/12,443 (4)	1.04 (0.88–1.23)	0.77 (0.58–1.03)
Diuretics	390/4,315 (9)	1,052/12,443 (9)	1.08 (0.95–1.22)	0.85 (0.68–1.06)

N/D = not determined.

\*Excessive alcohol consumption is 14 units or more a week for women and 21 units or more a week for men.

†Excessive coffee consumption was defined as 42 cups a week and more.

‡PPI: proton pump inhibitor.

\*\*H2RA: histamine-2 receptor antagonist.

§NSAIDs: non-steroidal anti-inflammatory drugs.

¶Antiplatelet therapy: low-dose acetylsalicylic acid, carbasalate calcium, clopidogrel and dipyridamol are taken together.

doi:10.1371/journal.pone.0069876.t001

problems. The EQ-5D tariffs were calculated by using Dutch coefficients for Time Trade Off tariffs [29]. The EQ-5D questionnaire also contains a visual analogue scale (EQ VAS), ranging from the worst imaginable health status to the best imaginable health status.

We defined excessive consumption of alcohol as  $\geq 14$  units (women) or  $\geq 21$  units (men) per week [30]. Body mass index (BMI in kg/m<sup>2</sup>) was categorized in  $< 25$  (normal weight) and 25 or more (overweight or obese) [31]. Excessive coffee consumption was defined as 42 cups or more per week [25,32].

### Statistical Analysis

We analysed data using Statistical Package for the Social Sciences (SPSS), version 16.0 (IBM Corporation, New York, United States). Frequency tables were provided for respondents' characteristics and for secondary outcomes. Pearson's chi squared ( $\chi^2$ ) analysis was used to compare categorical variables between respondents with and without presence of gastrointestinal symp-

oms. Continuous variables were compared between the two groups using Student's T-test or Mann-Whitney U method whenever appropriate. We calculated presence of various symptoms at various ages by calculating symptom presence per 10 years. Univariable and multivariable logistic regression analysis were performed to identify factors associated with gastrointestinal symptoms. Odds ratios and 95% confidence intervals were stated. Covariates were included in multivariable regression analysis based on a predefined conceptual model that was based on published literature. We also included covariates if they were univariably associated with the primary outcome ( $p < 0.01$ ).

Health-related quality of life was compared between respondents with and without gastrointestinal symptoms. The 5 domains of the EQ-5D questionnaire were compared using chi squared ( $\chi^2$ ) analysis. Dutch utility scores for every individual symptom in persons reporting gastrointestinal symptoms were calculated to assess the impact of an individual symptom on health-related quality of life. Correlation between gastrointestinal symptom score

**Table 2.** Type and frequency of upper gastrointestinal symptoms in respondents experiencing gastrointestinal symptoms.

	Number of respondents, n/N (%)
<b>Epigastric pain</b>	
<b>In general</b>	1,407/3,842 (36.6)
<b>During daytime</b>	1,422/3,565 (39.9)
<b>At night</b>	867/3,452 (25.1)
<b>Heartburn</b>	
<b>In general</b>	1,366/3,916 (34.9)
<b>During daytime</b>	1,250/3,537 (35.3)
<b>At night</b>	953/3,494 (27.3)
<b>Regurgitation</b>	1,545/4,012 (38.5)
<b>Belching</b>	1,884/4,166 (45.2)
<b>Empty feeling</b>	1,008/4,039 (25.0)
<b>Bloating</b>	2,627/4,164 (63.1)
<b>Nausea</b>	1,278/4,139 (30.9)
<b>Vomiting</b>	327/4,109 (8.0)
<b>Loss of appetite</b>	796/4,119 (19.3)
<b>Early satiety</b>	1,409/4,121 (34.2)
<b>Haematemesis</b>	36/4,091 (0.9)
<b>Dysphagia</b>	
<b>For liquids</b>	141/4,088 (3.4)
<b>For solid food</b>	257/3,957 (6.5)

doi:10.1371/journal.pone.0069876.t002

(VAS) and health-related quality of life (EQ VAS) was calculated with a Spearman correlation. A  $p$ -value  $< 0.01$  was assumed to be statistically significant.

## Results

A total of 18,317 (35%) questionnaires were returned, of which 742 returned unopened and uncompleted. After applying our predetermined exclusion criteria, a total of 16,758 questionnaires were included in our analyses (**Figure 1**). In total, 4,315 persons (26%) reported gastrointestinal symptoms, with a median symptom duration of 8 years (interquartile range 3–18 years). Compared to participants not reporting symptoms, those with gastrointestinal symptoms were younger ( $48.9 \pm 16$  vs.  $50.2 \pm 16$  years), more often female (66% vs. 53%), and reported more frequently use of any medication (overall 80% vs 67%; **Table 1**).

The most frequently reported upper gastrointestinal symptoms were bloating (63%) and belching (45%; **Table 2**). Flatulence (71%) and borborygmi (60%) were the most frequently reported lower gastrointestinal tract symptoms (**Table 3**). Distribution of symptom presence among different age categories is depicted in **Table 4**.

The overall prevalence of gastrointestinal symptoms decreased with ageing. This was apparent in females ( $P < 0.01$ ), but not in males ( $P = 0.22$ ; **Table S1**). There was no effect of Body Mass Index on upper versus lower gastrointestinal symptoms (data not shown).

## Factors Associated with Gastrointestinal Symptoms

We found that respondents with gastrointestinal symptoms more frequently reported acid suppressive medication use. Other

**Table 3.** Type and frequency of lower gastrointestinal symptoms in respondents experiencing gastrointestinal symptoms.

	Number of respondents, n/N (%)
<b>Lower abdominal pain</b>	
<b>In general</b>	1,755/4,075 (43.1)
<b>Postprandial</b>	1,176/3,477 (33.8)
<b>Pre-prandial</b>	726/3,379 (21.5)
<b>No reduction after defecation</b>	867/3,338 (26.0)
<b>Flatulence</b>	2,965/4,193 (70.7)
<b>Borborygmi</b>	2,479/4,138 (59.9)
<b>Abnormal defecation</b>	
<b>Black stools</b>	338/3,714 (9.1)
<b>Blood</b>	187/3,708 (5.0)
<b>Mucous</b>	557/3,751 (14.8)
<b>Frequently hard</b>	1,418/3,810 (37.2)
<b>Diarrhoea</b>	1,330/3,812 (34.9)
<b>Constipation</b>	1,060/3,859 (27.5)
<b>Alternately solid or loose</b>	1,939/3,979 (48.7)
<b>Frequently painful</b>	908/3,818 (23.8)
<b>Strong urgency</b>	1,541/3,853 (40.0)
<b>Incomplete</b>	1,143/3,811 (30.0)
<b>Fatty stools</b>	1,012/3,882 (26.1)

doi:10.1371/journal.pone.0069876.t003

factors that were also more frequently reported in respondents with gastrointestinal symptoms are depicted in **Table 1**.

After adjustment, female gender (adjusted OR (aOR) 1.59, 95% CI 1.43–1.77), asthma/COPD (aOR 1.47, 95% CI 1.21–1.79), use of paracetamol (aOR 1.33, 95% CI 1.20–1.47), antidepressants (aOR 1.56, 95% CI 1.22–2.00) and use of acid-suppressive medication (antacids aOR 4.22, 95% CI 3.53–5.05, H2RAs aOR 9.93, 95% CI 6.72–14.7, PPIs aOR 9.29, 95% CI 7.91–10.9) remained independently associated with a higher risk for presence of gastrointestinal symptoms (**Table 1**). Age  $\geq 65$  years (aOR 0.75, 95% CI 0.65–0.87), and use of statins (aOR 0.75, 95% CI 0.61–0.93) were independently associated with a lower risk for presence of gastrointestinal symptoms. In the univariable analysis obesity was associated with presence of gastrointestinal symptoms (OR 1.15, 95% CI 1.10–1.31), but this association was lost after adjustment (aOR 1.02, 95% CI 0.92–1.13).

## Health-related Quality of Life

The mean utility for health-related quality of life was statistically significantly lower for respondents with gastrointestinal symptoms (0.81, SD 0.21) compared to respondents without gastrointestinal symptoms (0.92, SD 0.14,  $p < 0.01$ ). This difference was statistically significant ( $p < 0.01$ ) for all dimensions, and most pronounced for dimensions “pain/discomfort”, “anxiety/depression”, and “usual activities” (**Table 5**). The gastrointestinal symptom score (VAS) correlated negatively with health-related quality of life (EQ VAS) with a Spearman correlation of  $-0.57$  ( $p < 0.01$ ), indicating that persons with more severe gastrointestinal symptoms reported a lower health-related quality of life. The following individual symptoms were associated with the lowest health-related quality of life: haematemesis (0.54, SD 0.32), dysphagia for liquid (0.59, SD

**Table 4.** Symptom presence in respondents with gastrointestinal symptoms at various age categories.

	Age categories					
	18–30 years	31–40 years	41–50 years	51–60 years	61–70 years	≥71 years
	n/N (%)	n/N (%)	n/N (%)	n/N (%)	n/N (%)	n/N (%)
<b>Epigastric pain in general</b>	257/650 (39.5)	238/627 (38.0)	303/799 (37.9)	323/856 (37.7)	196/594 (33.0)	88/305 (28.9)
<b>Belching</b>	335/672 (49.9)	288/651 (44.2)	396/870 (45.5)	428/932 (45.9)	278/678 (41.0)	153/349 (43.8)
<b>Bloating</b>	486/667 (72.9)	441/647 (68.2)	579/865 (66.9)	583/942 (61.9)	351/678 (51.8)	181/352 (51.4)
<b>Heartburn in general</b>	184/666 (27.6)	223/636 (35.1)	321/822 (39.1)	324/853 (38.0)	200/614 (32.6)	108/314 (34.4)
<b>Borborygmi</b>	511/669 (76.4)	411/644 (63.8)	523/864 (60.5)	518/930 (55.7)	331/669 (49.5)	179/350 (51.1)
<b>Constipation</b>	237/654 (36.2)	194/618 (31.4)	224/808 (27.7)	203/851 (23.9)	111/604 (18.4)	86/311 (27.7)

doi:10.1371/journal.pone.0069876.t004

0.32) and solid intake (0.62, SD 0.30) and vomiting (0.66, SD 0.30; **Table S2**).

## Discussion

We found that 26% of the general population reported gastrointestinal symptoms, with a median duration of eight years. Our study identifies female gender, asthma/COPD, use of paracetamol, antidepressants and acid suppressive medication use as risk factors that were independently associated with a higher prevalence of gastrointestinal symptoms. Older age and statin use protected against gastrointestinal symptoms. Respondents with gastrointestinal symptoms had an impaired health-related quality of life. In comparison to other, older, studies in the field [1,3–12],

we found a similar prevalence of gastrointestinal symptoms in the community. This suggests that the effect of time is limited, although there are a plethora of differences between our study and others, most importantly the definitions used to assess prevalence of gastrointestinal symptoms.

We found that females more frequently reported gastrointestinal symptoms, which is in line with other studies regarding gastrointestinal symptoms [9,25,33]. In our study, presence of asthma or COPD was an independent risk factor. Presence of asthma is associated with GERD, [34,35], and recent studies indicate an increased prevalence of GERD symptoms in patients with COPD [36–38]. Medication use, and especially paracetamol, antidepressants, and acid-suppressive medication contributed

**Table 5.** Health-related quality of life in respondents with and without gastrointestinal symptoms.

EQ-5D dimension	Respondents with gastrointestinal symptoms	Respondents without gastrointestinal symptoms	P-value
	n/N (%)	n/N (%)	
<b>Mobility</b>			<0.001
No problems	3,440/4,203 (81.8)	10,880/12,194 (89.2)	
Some problems	745/4,203 (17.7)	1,290/12,194 (10.6)	
Extreme problems	18/4,203 (0.4)	24/12,194 (0.2)	
<b>Self-care</b>			<0.001
No problems	4,039/4,191 (96.4)	11,904/12,154 (97.9)	
Some problems	134/4,191 (3.2)	219/12,154 (1.8)	
Extreme problems	18/4,191 (0.4)	31/12,154 (0.3)	
<b>Usual activities</b>			<0.001
No problems	3,179/4,213 (75.5)	11,029/12,173 (90.6)	
Some problems	952/4,213 (22.6)	1,065/12,173 (8.7)	
Extreme problems	82/4,213 (1.9)	79/12,173 (0.6)	
<b>Pain/discomfort</b>			<0.001
No problems	1,715/4,209 (40.7)	9,424/12,128 (77.7)	
Some problems	2,263/4,209 (53.8)	2,559/12,128 (21.1)	
Extreme problems	231/4,209 (5.5)	145/12,128 (1.2)	
<b>Anxiety/depression</b>			<0.001
No problems	2,893/4,215 (68.6)	10,559/12,131 (87.0)	
Some problems	1,185/4,215 (28.1)	1,485/12,131 (12.2)	
Extreme problems	137/4,215 (3.3)	87/12,131 (0.7)	

doi:10.1371/journal.pone.0069876.t005

significantly to presence of gastrointestinal symptoms in our large population-based survey. The independent association found for paracetamol, probably stems from the use of paracetamol as a panacea for gastrointestinal symptoms. We surmise that this hypothesis also applies to the relation between acid-suppressive medication and gastrointestinal symptoms. The association between antidepressants and gastrointestinal symptoms is complex due to the interactions between: 1) depression and gastrointestinal symptoms; 2) depression and antidepressant use, and 3) antidepressant use and gastrointestinal symptoms [39–48].

A total of 11% of our studied population reported PPI use, 2% H2RA use and 6% antacid use. This is much lower than the use of so-called ‘indigestion remedies’ in a study by Jones *et al.* prior to the PPI era, in which 47–55% of respondents reported any use of this medication class [3]. Use of PPIs was strongly associated with gastrointestinal symptom presence in our study (adjusted OR 9.28, 95% CI 7.91–10.9). This can be explained by a combination of indication bias, partial responsiveness on PPI therapy and assessment of both upper and lower gastrointestinal symptom presence. However, the prevalence of gastrointestinal symptoms would be even higher if we would include respondents with acid suppressive medication without current gastrointestinal symptoms in our prevalence.

In a recently published study, the prevalence of *upper* gastrointestinal symptoms in The Netherlands, the country where our study was performed, was 24% [21]. We found an almost similar prevalence (26%), but we assessed both upper *and* lower gastrointestinal symptoms. We found that the majority of respondents with gastrointestinal symptoms had both upper and lower gastrointestinal symptoms. Respondents with upper gastrointestinal symptoms have a higher risk for associated lower gastrointestinal symptoms. This is in line with a Japanese study that reported overlap of GERD, functional dyspepsia and IBS in 45% of their studied population [23]. Moreover, in the natural history of functional gastrointestinal disorders many patients frequently switch between upper and lower gastrointestinal symptoms [49].

We also reported the impact of gastrointestinal symptoms on health-related quality of life. Gastrointestinal symptoms were associated with a disutility of 0.11, which was in line with a disutility for dyspeptic symptoms of 0.09 in another study [50]. Furthermore, we observed that more severe symptoms correlated with a lower health-related quality of life (**Table S2**). By presenting a wide variety of utilities, we have delivered input for cost-utility studies. These studies become more and more important, and are incorporated in clinical guidelines, e.g. by the National Institute for Health and Care and Excellence (NICE).

The major strength of our study is that we examined commonly experienced symptoms in the community by use of a broad definition. Secondly, in order to attain a representative sample, persons were randomly selected via databases of local authorities without stringent in- and exclusion criteria. Third, we studied gastrointestinal symptoms overall and per symptom instead of in clusters of gastrointestinal symptoms.

## References

1. Talley NJ, Zinsmeister AR, Schleck CD, Melton LJ, 3rd (1992) Dyspepsia and dyspepsia subgroups: a population-based study. *Gastroenterology* 102: 1259–1268.
2. Nyrop KA, Palsson OS, Levy RL, Korff MV, Feld AD, et al. (2007) Costs of health care for irritable bowel syndrome, chronic constipation, functional diarrhoea and functional abdominal pain. *Aliment Pharmacol Ther* 26: 237–248.
3. Jones RH, Lydeard SE, Hobbs FD, Kenkre JE, Williams EI, et al. (1990) Dyspepsia in England and Scotland. *Gut* 31: 401–405.

Our study design comes with limitations. We cannot exclude response bias, as our response rate was 35%. Response rates in epidemiological studies are declining the last decades and this problem is faced by multiple researchers [51,52]. A study by Galea *et al.* describes that a low response rate is not inevitably leading to substantial changes in outcomes [51]. Since our study was performed with postal questionnaires, in comparison to digital surveys, our response rate is actually not that low and still within the range of an acceptable response rate according to Galea *et al.* Due to concealment we were not able to perform non-responder research. We tried to minimize this bias by inviting all subjects with a personalized cover letter, and we asked explicitly to return the questionnaire, irrespective of presence of gastrointestinal symptoms. Seventy-four percent of all responders did not report the presence of gastrointestinal symptoms. Furthermore, the prevalence of co-morbidities in our study cohort resembles the prevalence in the general population [53]. Therefore, we assume that response bias might be limited. We also cannot exclude that bias was introduced by exclusion of individuals with incomplete information about gastrointestinal symptoms.

The results of our study will refresh awareness among healthcare providers on the high prevalence of gastrointestinal symptoms in the general population. Future research should focus on new targets to effectively treat patients with gastrointestinal symptoms, as we have shown that even many users of acid suppressive medication still report presence of symptoms.

In conclusion, despite increased treatment options and alterations in risk factors, the prevalence of gastrointestinal symptoms in the western community remains high and is associated with a considerable decrease in health-related quality of life.

## Supporting Information

### Table S1 Prevalence of gastrointestinal symptoms per age category and gender.

(DOC)

### Table S2 Impact of individual gastrointestinal symptoms on health-related quality of life.

(DOC)

## Acknowledgments

We gratefully acknowledge J.P.H. Drenth for critically revising the manuscript.

## Author Contributions

Performed the experiments: MMT JJF. Analyzed the data: MMT JJF MGHvO. Designed the questionnaire: MGHvO LGMvR RJFL JBMJJ. Tested the questionnaire in a previous pilot study: TE MGHvO LGMvR RJFL JBMJJ. Collected data of the present study: TE. Prepared the first draft of the manuscript: MMT MGHvO. Participated sufficiently in the adaptation of the first version of the manuscript and approved submission of the current manuscript: MMT JJF LGMvR TE JBMJJ RJFL MGHvO. Performed database management: LGMvR.

4. Kay L, Jorgensen T (1994) Epidemiology of upper dyspepsia in a random population. Prevalence, incidence, natural history, and risk factors. *Scand J Gastroenterol* 29: 2–6.
5. Agreus L, Svarisudd K, Nyren O, Tibblin G (1995) Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. *Gastroenterology* 109: 671–680.
6. Bernersen B, Johnsen R, Straume B (1996) Non-ulcer dyspepsia and peptic ulcer: the distribution in a population and their relation to risk factors. *Gut* 38: 822–825.

7. Jones R, Lydeard S (1989) Prevalence of symptoms of dyspepsia in the community. *BMJ* 298: 30–32.
8. Penston JG, Pounder RE (1996) A survey of dyspepsia in Great Britain. *Aliment Pharmacol Ther* 10: 83–89.
9. Talley NJ, Zinsmeister AR, Schleck CD, Melton IJ, 3rd (1994) Smoking, alcohol, and analgesics in dyspepsia and among dyspepsia subgroups: lack of an association in a community. *Gut* 35: 619–624.
10. Holtmann G, Goebell H, Talley NJ (1994) Dyspepsia in consultants and non-consultants: prevalence, health-care seeking behaviour and risk factors. *European Journal of Gastroenterology & Hepatology* 6: 917–924.
11. Shaib Y, El-Serag HB (2004) The prevalence and risk factors of functional dyspepsia in a multiethnic population in the United States. *Am J Gastroenterol* 99: 2210–2216.
12. El-Serag HB, Talley NJ (2004) Systemic review: the prevalence and clinical course of functional dyspepsia. *Aliment Pharmacol Ther* 19: 643–654.
13. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, et al. (2007) Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. *Gut* 56: 772–781.
14. Miendje Deyi VY, Vanderpas J, Bontems P, Van den Borre C, De Koster E, et al. (2011) Marching cohort of Helicobacter pylori infection over two decades (1988–2007): combined effects of secular trend and population migration. *Epidemiol Infect* 139: 572–580.
15. van Marrewijk CJ, Mujakovic S, Fransen GA, Numans ME, de Wit NJ, et al. (2009) Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H<sub>2</sub>-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled trial. *Lancet* 373: 215–225.
16. Fox M, Forgacs I (2006) Gastro-oesophageal reflux disease. *BMJ* 332: 88–93.
17. Rotman SR, Bishop TF (2013) Proton Pump Inhibitor Use in the U.S. Ambulatory Setting, 2002–2009. *PLoS ONE* 8.
18. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, et al. (2008) ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. *J Am Coll Cardiol* 52: 1502–1517.
19. Delgado-Aros S, Locke GR, 3rd, Camilleri M, Talley NJ, Fett S, et al. (2004) Obesity is associated with increased risk of gastrointestinal symptoms: a population-based study. *Am J Gastroenterol* 99: 1801–1806.
20. Cremonini F, Locke GR, 3rd, Schleck CD, Zinsmeister AR, Talley NJ (2006) Relationship between upper gastrointestinal symptoms and changes in body weight in a population-based cohort. *Neurogastroenterol Motil* 18: 987–994.
21. Haag S, Andrews JM, Gapasin J, Gerken G, Keller A, et al. (2011) A 13-nation population survey of upper gastrointestinal symptoms: prevalence of symptoms and socioeconomic factors. *Aliment Pharmacol Ther* 33: 722–729.
22. Halder SL, Locke GR, 3rd, Talley NJ, Fett SL, Zinsmeister AR, et al. (2004) Impact of functional gastrointestinal disorders on health-related quality of life: a population-based case-control study. *Aliment Pharmacol Ther* 19: 233–242.
23. Kaji M, Fujiwara Y, Shiba M, Kohata Y, Yamagami H, et al. (2010) Prevalence of overlaps between GERD, FD and IBS and impact on health-related quality of life. *J Gastroenterol Hepatol* 25: 1151–1156.
24. Koloski NA, Talley NJ, Boyce PM (2000) The impact of functional gastrointestinal disorders on quality of life. *Am J Gastroenterol* 95: 67–71.
25. van Kerkhoven LA, Eikendal T, Laheij RJ, van Oijen MG, Jansen JB (2008) Gastrointestinal symptoms are still common in a general Western population. *Neth J Med* 66: 18–22.
26. Bovenschen HJ, Janssen MJ, van Oijen MG, Laheij RJ, van Rossum LG, et al. (2006) Evaluation of a gastrointestinal symptoms questionnaire. *Dig Dis Sci* 51: 1509–1515.
27. Likert R (1932) A technique for the measurement of attitudes. *Archives of Psychology* 140.
28. Brooks R (1996) EuroQol: the current state of play. *Health Policy* 37: 53–72.
29. Lamers LM, Stalmeier PF, McDonnell J, Krabbe PF, van Busschbach JJ (2005) [Measuring the quality of life in economic evaluations: the Dutch EQ-5D tariff]. *Ned Tijdschr Geneesk* 149: 1574–1578.
30. (NHG) DCoGP (2011) Multidisciplinary guideline cardiovascular risk management.
31. (2000) Obesity: preventing and managing the global epidemic. Report of a WHO consultation. *World Health Organ Tech Rep Ser* 894: i–xii, 1–253.
32. van Dam RM (2006) [Coffee consumption and the decreased risk of diabetes mellitus type 2]. *Ned Tijdschr Geneesk* 150: 1821–1825.
33. Piessevaux H, De Winter B, Louis E, Muls V, De Looze D, et al. (2009) Dyspeptic symptoms in the general population: a factor and cluster analysis of symptom groupings. *Neurogastroenterol Motil* 21: 378–388.
34. Havemann BD, Henderson CA, El-Serag HB (2007) The association between gastro-oesophageal reflux disease and asthma: a systematic review. *Gut* 56: 1654–1664.
35. Powell N, Huntley B, Beech T, Knight W (2008) Upper gastrointestinal symptoms and asthma: a manifestation of allergy? *Gut* 57: 1026–1027.
36. Gadel AA, Mostafa M, Younis A, Haleem M (2012) Esophageal motility pattern and gastro-oesophageal reflux in chronic obstructive pulmonary disease. *HepatoGastroenterology* 59: 2498–2502.
37. Kamble NL, Khan NA, Kumar N, Nayak HK, Daga MK (2012) A study of gastro-oesophageal reflux disease (GORD) in patients with mild to moderate COPD in India. *Respirology*.
38. Liang BM, Feng YL (2012) Association of gastroesophageal reflux disease symptoms with stable chronic obstructive pulmonary disease. *Lung* 190: 277–282.
39. Van Oudenhove L, Vandenberghe J, Demyttenaere K, Tack J (2010) Psychosocial factors, psychiatric illness and functional gastrointestinal disorders: a historical perspective. *Digestion* 82: 201–210.
40. Levy RL, Olden KW, Naliboff BD, Bradley LA, Francisconi C, et al. (2006) Psychosocial aspects of the functional gastrointestinal disorders. *Gastroenterology* 130: 1447–1458.
41. Gonella G, Bagnoli G, Ecarri U (1990) Fluvoxamine and imipramine in the treatment of depressive patients: a double-blind controlled study. *Curr Med Res Opin* 12: 177–184.
42. Norton KR, Sireling LI, Bhat AV, Rao B, Paykel ES (1984) A double-blind comparison of fluvoxamine, imipramine and placebo in depressed patients. *J Affect Disord* 7: 297–308.
43. Trindade E, Menon D, Topfer LA, Coloma C (1998) Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. *CMAJ* 159: 1245–1252.
44. Hojo M, Miwa H, Yokoyama T, Ohkusa T, Nagahara A, et al. (2005) Treatment of functional dyspepsia with anti-anxiety or antidepressive agents: systematic review. *J Gastroenterol* 40: 1036–1042.
45. Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P (2009) Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. *Gut* 58: 367–378.
46. Rahimi R, Nikfar S, Rezaie A, Abdollahi M (2009) Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis. *World J Gastroenterol* 15: 1548–1553.
47. Mak AD, Wu JC, Chan Y, Chan FK, Sung JJ, et al. (2012) Dyspepsia is strongly associated with major depression and generalised anxiety disorder - a community study. *Aliment Pharmacol Ther* 36: 800–810.
48. Dong YY, Chen FX, Yu YB, Du C, Qi QQ, et al. (2013) A school-based study with Rome III criteria on the prevalence of functional gastrointestinal disorders in Chinese college and university students. *PLoS One* 8: e54183.
49. Halder SL, Locke GR, 3rd, Schleck CD, Zinsmeister AR, Melton IJ, 3rd, et al. (2007) Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study. *Gastroenterology* 133: 799–807.
50. Groeneveld PW, Lieu TA, Fendrick AM, Hurley LB, Ackerson LM, et al. (2001) Quality of life measurement clarifies the cost-effectiveness of Helicobacter pylori eradication in peptic ulcer disease and uninvestigated dyspepsia. *Am J Gastroenterol* 96: 338–347.
51. Galea S, Tracy M (2007) Participation rates in epidemiologic studies. *Ann Epidemiol* 17: 643–653.
52. Morton LM, Cahill J, Hartge P (2006) Reporting participation in epidemiologic studies: a survey of practice. *Am J Epidemiol* 163: 197–203.
53. Baan CA, Poos MJJC (2011) Hoe vaak komt diabetes mellitus voor en hoeveel mensen sterven eraan? In: Ministry of Health WaS, editor. National Public Health Compass: National Institute of Public Health and the Environment (RIVM).